Abstract
The previous findings in vitro show high antiaggregation activity of newly synthesized cyclohexilammonium salt of 2‐[1‐ethil‐3‐methyl‐7‐(dioxotiethanyl‐3)xantinyl‐8‐thio]acetic acid. The current findings are received in vivo on the model of collagen‐adrenaline thrombosis according to G.S. Di Minno subject to the FASEB Statement of Principles for the use of animals in research and education. Efficacy endpoint is the number of survived animals in comparison with the test group and comparator agents since the injection into the tail vein suspended matter of collagen and adrenalin upto the moment of death or during 14 days of monitoring. The survival analysis was carried out with the help of Kaplan‐Meier method. The difference in survival between the groups was assessed with the help of Wilkonson criterion.Intraperinoneal injection of the new secondary 1‐ethylxantin reduced mortality in lab mice by 1,3 times (P1<0,01) in comparison with the camparator agents. Thus, cyclohexilammonium salt of 2‐[1‐ethil‐3‐methyl‐7‐(dioxotiethanyl‐3)xantinyl‐8‐thio]acetic acid is a potential antithrombotic agent.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
